Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...